<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2005">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278119</url>
  </required_header>
  <id_info>
    <org_study_id>17-01005</org_study_id>
    <secondary_id>R01AG056031</secondary_id>
    <nct_id>NCT03278119</nct_id>
  </id_info>
  <brief_title>Sleep Aging and Risk for Alzheimer's 2.0</brief_title>
  <acronym>SARA</acronym>
  <official_title>Sleep Aging and Risk for Alzheimer's Resubmission 2.0</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-related sleep changes and common sleep disorders like obstructive sleep apnea (OSA) may&#xD;
      increase amyloid burden and represent risk factors for cognitive decline in the elderly. We&#xD;
      will directly interrogate the brain using a 2-night nocturnal polysomnography (NPSG) and&#xD;
      amyloid deposition using C-PiB PET/MR both at baseline and at the 24-month follow-up. This&#xD;
      study has the potential to identify the mechanisms by which age-related sleep changes&#xD;
      contribute to AD neurodegeneration in cognitively normal elderly, the group that could profit&#xD;
      the most from sleep preventive strategies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establishing how mild-to-moderate OSA increases AD risk will inform novel preventive therapies for AD.</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishing that SWS quality is associated with longitudinal amyloid deposition will identify a key mechanism by which age increases AD risk.</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Sleep Apnea</arm_group_label>
    <description>Overall 56&#xD;
both male and female&#xD;
age group 55 to 75 years, having mild to severe obstructive sleep apnea&#xD;
in good general health with no significant comorbidities&#xD;
Located for the most part in boroughs of New York City</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Sleep Apnea</arm_group_label>
    <description>Overall 56&#xD;
both male and female&#xD;
age group 55 to 75 years, without OSA&#xD;
in good general health with no significant comorbidities&#xD;
Located for the most part in boroughs of New York City</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET Scan and nocturnal polysomnography</intervention_name>
    <description>Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables</description>
    <arm_group_label>No Sleep Apnea</arm_group_label>
    <arm_group_label>Sleep Apnea</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        112 subjects with normal sleep breathing (non-OSA) or mild to moderate OSA (AHI4%&lt;30).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible to participate in this study, an individual must meet all of the following&#xD;
        criteria:&#xD;
&#xD;
          -  Male and female subjects with normal cognition and 55-75 years.&#xD;
&#xD;
          -  Within normal limits on neurological and psychiatric examinations. All subjects&#xD;
             enrolled will have a CDR=0.&#xD;
&#xD;
          -  All subjects will have had a minimum of 12 years of education. Among minority subjects&#xD;
             &gt;80% of the elderly individuals coming to the NYU-ADC meet this criterion. The&#xD;
             education restriction reduces performance variance on cognitive test measures and&#xD;
             improves the sensitivity for detecting pathology and disease progression using the&#xD;
             robust norms available at NYU. Given most subjects will meet this criterion we do not&#xD;
             consider this a major selection bias or generalization limitation for this study.&#xD;
&#xD;
          -  An informed family member or life-partner (preferably bed-partner) will be interviewed&#xD;
             to confirm the reliability of the subject interview.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          -  History of brain tumor, MRI evidence of brain damage or brain disease including&#xD;
             significant trauma, hydrocephalus, seizures, mental retardation or other serious&#xD;
             neurological disorder (e.g. Parkinson's disease or other movement disorders).&#xD;
&#xD;
          -  Significant history of alcoholism or drug abuse.&#xD;
&#xD;
          -  History of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long&#xD;
             history of major depression).&#xD;
&#xD;
          -  Geriatric Depression Scale (short form)&gt;6.&#xD;
&#xD;
          -  Insulin dependent diabetes.&#xD;
&#xD;
          -  Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological&#xD;
             conditions.&#xD;
&#xD;
          -  Physical impairment of such severity as to adversely affect the validity of&#xD;
             psychological testing.&#xD;
&#xD;
          -  Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard&#xD;
             for MRI imaging.&#xD;
&#xD;
          -  Medications affecting cognition: Narcotic analgesics, chronic use of medications with&#xD;
             anticholinergic activity, anti-Parkinsonian medications (carbidopa/levodopa,&#xD;
             amantadine, bromocriptine, selegiline). Others: amphetamines, amphetamine-like&#xD;
             compounds, appetite suppressants, phenothiazines, reserpine, buspirone, clonidine,&#xD;
             disulfiram, guanethidine, MAO inhibitors, theophylline, tricyclic antidepressants,&#xD;
             salicylates, cholinesterase inhibitors and memantine.&#xD;
&#xD;
          -  History of a first-degree family member with early onset (age &lt;60 years) dementia.&#xD;
&#xD;
          -  Irregular sleep-wake rhythms (based on the actigraphy recordings) or severe OSA&#xD;
             (AHI4%â‰¥30).&#xD;
&#xD;
          -  Chronic use of antidepressants and melatonin are allowed.&#xD;
&#xD;
          -  Excessive daytimes sleepiness (Epworth Sleepiness Scale &gt;10) or history of CVE&#xD;
             (arrhythmias, heart valve disease, cardiomyopathy, carotid or coronary artery disease&#xD;
             and chest pain) will not be allowed in the OSA groups.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Osorio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Langone Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriela Silva Albornoz</last_name>
    <phone>2122635053</phone>
    <email>Gabriela.SilvaAlbornoz@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zanetta Kovbasyuk</last_name>
    <phone>2122637563</phone>
    <email>zanetta.kovbasyuk@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Healthy Brain Aging and Sleep Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Osorio, M.D</last_name>
      <phone>212-263-3255</phone>
      <email>Ricardo.Osorio@nyulangone.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>October 27, 2022</last_update_submitted>
  <last_update_submitted_qc>October 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

